Navigation Links
Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
Date:7/7/2011

AMSTERDAM, July 7, 2011 /PRNewswire/ --


Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has filed a request for re-examination of the Marketing Authorisation Application for Glybera® with the European Medicines Agency. Glybera is a gene therapy for the genetic disorder lipoprotein lipase deficiency. The Company expects that the re-examination of the dossier will be completed by the end of 2011.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. The company's lead product Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD), is currently under review by the European Medicines Agency (EMA). If approved, Glybera will be the first gene therapy product to be marketed in Europe. AMT also has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "st
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
2. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
3. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
5. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
7. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications
10. Biochemist and Geneticist Ronald W. Davis Receives $500,000 Gruber Genetics Prize for Pioneering Work in the Development of Biotechnologies that Have Significantly Advanced the Fields of Molecular Genetics and Genomics
11. NIH grant ratchets up ASU research in molecular motors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... DIEGO , Dec. 15, 2014 ... three-dimensional biology company focused on delivering breakthrough 3D ... the industry and collaborators of its exVive3D TM ... made widely available in full commercial release on ... the field, resulting in several awards for innovation. ...
(Date:12/15/2014)... 2014  Origin Agritech Limited (NASDAQ GS: SEED) (" Origin ... crop seeds in China , today announced ... 2014 ended September 30, 2014, before the market opens on ... a teleconference on January 8, 2015, at 8:00 a.m. ET ... discuss the results. To participate in the call, please dial ...
(Date:12/13/2014)... CanDiag, Inc., a University of North Carolina at ... to OncoTab, Inc. , “The new name is ... said CEO and Chief Science Officer, Dr. Pinku Mukherjee, ... diagnostics to include imaging and therapies, and our new ... in 2011 by Dr. Mukherjee, an Irwin Belk Endowed ...
(Date:12/13/2014)... 2014 Clarassance, a privately held clinical-stage ... name: Therabron Therapeutics , Inc. The new name ... type of structure in the lungs similar to branches ... develop novel protein therapeutics for the treatment of respiratory ... change the name to mark the company's escalation into ...
Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... p.m. PT ... (5:00 p.m. ET), IRVINE, Calif., ... CO-Oximetry and,Measure-Through-Motion- and-Low-Perfusion pulse oximetry, today announced,it will release third quarter financial ... Monday, October 27, 2008., A conference call to review the results ...
... Calif., Oct. 15 SuperGen, Inc.,(Nasdaq: SUPG ... and,development of novel cancer therapies, today announced the ... EORTC-NCI-AACR Symposium on "Molecular,Targets and Cancer Therapeutics" on ... will review clinical and non-clinical advances,in the following ...
... SourceSolution, a leader in,search technology for the biotechnology ... target to launch a new initiative next month,which ... manufacturing and,research organizations (CMOs/CROs). The proprietary technology will ... Service (SaaS) database. The,database will allow users to ...
Cached Biology Technology:Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008 2SuperGen to Present Data at EORTC-NCI-AACR 2SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies 2
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... 2014  The Secure Identity & Biometrics Association ... announce the formation of The Airport Entry and ... Identity and Biometric Entry and Exit Solutions Framework ... support from BORDERPOL, the international non-profit organization that ... expertise regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... a serious environmental, economic and social problem worldwide as ... ecosystem functions, such as nutrient cycling. Despite substantial research, ... new habitats over native plants that technically should have ... is that these plants are more abundant in introduced ...
... Invasive plant species are a serious environmental, economic ... lost native biodiversity and ecosystem functions, such as nutrient ... about why some species dominate new habitats over native ... common but rarely tested assumption, say biologists, is that ...
... (Feb. 1, 2011) -- Rice University bioengineers and physician-scientists ... have successfully destroyed tumors of human brain cancer cells ... treatment that zaps glioma tumors with heat. The tests ... tumors with heat and avoid the unwanted side effects ...
Cached Biology News:Home and away: How do invasive plant species dominate native species? 2Home and away: Are invasive plant species really that special? 2Early tests find nanoshell therapy effective against brain cancer 2
...
... Kits are designed to speed up the PCR ... products, regardless of sequence or type of polymerase ... those that are difficult to clone by other ... or code for potentially detrimental proteins can be ...
... is the standard water based mounting medium ... the permanent preservation of peroxidase and alkaline ... to use and exhibits excellent optical characteristics. ... mounting medium that permits the long-term storage ...
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
Biology Products: